AR-110 , has demonstrated to be superior to Zytiga and Xtandi for cancer cell to develop resistance to.
In preclinical studies, ARV-110 reduced AR levels by 95-98% in several prostate cancer cell lines. Additionally, in a mouse model inhibited tumor growth by up to 100%.
AR-110 may be available in a year or so, I may not be.
prostatecancernewstoday.com...
arvinas.com/therapeutic-pro...
Bob